晚期肺癌的个体化治疗已日趋完善,而相对较少的早期非小细胞肺癌个体化治疗仍然是个需要突破的命题。如何更加精确地为早期非小细胞肺癌患者提供个体化治疗方案,使患者能够在术后得到更高的生活质量及更长的生存时间,是我们目前临床需要面对的巨大挑战。
Although the individualized treatment of advanced lung cancer has been maturing,the relatively minority of individual treatment of early stage non-small cell lung cancer is still a proposition which need to break. The great challenge we have to face now is the mission to offer patients with early stage none-small cell lung cancer individualized treatment more exactly,to provide a higher postoperative quality and a longer survival time.